Clinical and immunological insights into chikungunya virus infection in people living with HIV
- 1Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Abstract
Chikungunya virus (CHIKV) is a globally emerging arthropod-borne virus causing widespread febrile outbreaks, with its endemic regions showing extensive geographical overlap with human immunodeficiency virus (HIV). Approximately 71% of people living with HIV (PLWH) reside in CHIKV high-risk areas globally, while the clinical features and underlying immunological interplay of CHIKV-HIV co-infection have not been systematically synthesized. This review integrates current evidence on CHIKV host immune responses, alongside the epidemiological characteristics, clinical manifestations, and immunopathological mechanisms of CHIKV infection in PLWH, to deliver integrated clinical and immunological insights into co-infection. Available data indicate that PLWH on suppressive antiretroviral therapy (ART) generally present with milder CHIKV disease, with potential mechanisms involving HIV-induced immune system alterations and direct antiviral activity of ART. This review provides an evidence-based framework for clinical management and public health prevention strategies for this vulnerable population.
Related
- Epidemiology of Chikungunya Virus Infection in the Philippines.
- Persistent neutralizing antibodies against chikungunya virus eight years after infection
- Clinical Outcomes and Hospital Resource Utilization Among Patients with Sepsis and COVID-19 Infection: Insights from the United States National Inpatient Sample Analysis, 2020-2022.
- Spatial analyses of infection and disease during chikungunya and Zika epidemics in Managua, Nicaragua
- Dengue and Chikungunya virus co-infection in fever cases attending a tertiary care hospital in Dhaka city
BibTeX
@article{gao2026clinical,
title = {{Clinical and immunological insights into chikungunya virus infection in people living with HIV}},
author = {Yuan Gao and Aiwei Zhu and Peng Xu and Ning Ding and Bin Su},
journal = {Biosafety and health},
year = {2026},
month = aug,
doi = {10.1016/j.bsheal.2026.08.002},
url = {https://europepmc.org/article/PMC/PMC13729072},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Clinical and immunological insights into chikungunya virus infection in people living with HIV
AU - Yuan Gao
AU - Aiwei Zhu
AU - Peng Xu
AU - Ning Ding
AU - Bin Su
PY - 2026
DA - 2026/08/17
JO - Biosafety and health
DO - 10.1016/j.bsheal.2026.08.002
UR - https://europepmc.org/article/PMC/PMC13729072
AB - Chikungunya virus (CHIKV) is a globally emerging arthropod-borne virus causing widespread febrile outbreaks, with its endemic regions showing extensive geographical overlap with human immunodeficiency virus (HIV). Approximately 71% of people living with HIV (PLWH) reside in CHIKV high-risk areas globally, while the clinical features and underlying immunological interplay of CHIKV-HIV co-infection have not been systematically synthesized. This review integrates current evidence on CHIKV host immune responses, alongside the epidemiological characteristics, clinical manifestations, and immunopathological mechanisms of CHIKV infection in PLWH, to deliver integrated clinical and immunological insights into co-infection. Available data indicate that PLWH on suppressive antiretroviral therapy (ART) generally present with milder CHIKV disease, with potential mechanisms involving HIV-induced immune system alterations and direct antiviral activity of ART. This review provides an evidence-based framework for clinical management and public health prevention strategies for this vulnerable population.
SN - 2590-0536
SN - 2096-6962
ER -